Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The study is an open-label extension study, offering patients who participated and completed
previous study 901 to continue treatment with DiaPep277 and clinical follow-up, for 2
additional years. The expectation is first to demonstrate that extended treatment with
DiaPep277 is safe and second to evaluate the long-term effectiveness of treatment. Only
patients who completed the previous 2-year study and still have beta-cell function above a
threshold level will be eligible for this extension study.